CN1481806A - 黄芪总苷注射剂制剂及其制备方法 - Google Patents
黄芪总苷注射剂制剂及其制备方法 Download PDFInfo
- Publication number
- CN1481806A CN1481806A CNA031419275A CN03141927A CN1481806A CN 1481806 A CN1481806 A CN 1481806A CN A031419275 A CNA031419275 A CN A031419275A CN 03141927 A CN03141927 A CN 03141927A CN 1481806 A CN1481806 A CN 1481806A
- Authority
- CN
- China
- Prior art keywords
- radix astragali
- injection
- astragaloside
- ethanol
- astragali total
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 49
- 239000007924 injection Substances 0.000 title claims abstract description 49
- 239000000203 mixture Substances 0.000 title claims 2
- 238000002360 preparation method Methods 0.000 title abstract description 19
- 229940107666 astragalus root Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 title 1
- 229930182490 saponin Natural products 0.000 title 1
- 150000007949 saponins Chemical class 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 47
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 39
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 claims abstract description 29
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 claims abstract description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003085 diluting agent Substances 0.000 claims abstract description 8
- 229960002903 benzyl benzoate Drugs 0.000 claims abstract description 5
- 239000006184 cosolvent Substances 0.000 claims abstract description 5
- 230000003204 osmotic effect Effects 0.000 claims abstract description 3
- 239000009636 Huang Qi Substances 0.000 claims description 42
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 30
- 229930182470 glycoside Natural products 0.000 claims description 24
- 150000002338 glycosides Chemical class 0.000 claims description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 13
- 239000008103 glucose Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 11
- 239000003978 infusion fluid Substances 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 abstract 1
- 229940113088 dimethylacetamide Drugs 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 229920000151 polyglycol Polymers 0.000 abstract 1
- 239000010695 polyglycol Substances 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 235000013388 Agathosma crenulata Nutrition 0.000 description 8
- 235000009269 Barosma crenulata Nutrition 0.000 description 8
- 229940062650 buchu Drugs 0.000 description 8
- 238000012856 packing Methods 0.000 description 8
- 244000152526 Agathosma crenulata Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 208000010125 myocardial infarction Diseases 0.000 description 7
- 206010061216 Infarction Diseases 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000007574 infarction Effects 0.000 description 6
- 238000010253 intravenous injection Methods 0.000 description 6
- 230000000302 ischemic effect Effects 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010000891 acute myocardial infarction Diseases 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 229910000831 Steel Inorganic materials 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 239000010959 steel Substances 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 244000137282 Agathosma betulina Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031419275A CN100367969C (zh) | 2003-07-29 | 2003-07-29 | 黄芪总苷注射剂制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031419275A CN100367969C (zh) | 2003-07-29 | 2003-07-29 | 黄芪总苷注射剂制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1481806A true CN1481806A (zh) | 2004-03-17 |
CN100367969C CN100367969C (zh) | 2008-02-13 |
Family
ID=34155534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031419275A Expired - Fee Related CN100367969C (zh) | 2003-07-29 | 2003-07-29 | 黄芪总苷注射剂制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100367969C (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1314804C (zh) * | 2005-05-20 | 2007-05-09 | 上海中医药大学 | 内源基因超量表达技术提高黄芪甲苷含量 |
CN1785202B (zh) * | 2004-12-06 | 2010-12-01 | 天津天士力制药股份有限公司 | 一种治疗心血管疾病的药物组合物及其制备方法 |
CN101507747B (zh) * | 2009-03-21 | 2010-12-01 | 山西振东泰盛制药有限公司 | 黄芪总皂苷氯化钠注射液的制备方法 |
CN101502558B (zh) * | 2009-03-21 | 2011-05-11 | 山西振东泰盛制药有限公司 | 环糊精组合物制备黄芪总皂苷注射液的方法 |
US20120237625A1 (en) * | 2009-11-30 | 2012-09-20 | Amorepacific Corporation | Metabolism accelerating composition comprising astragali radix extract |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100346798C (zh) * | 2002-12-19 | 2007-11-07 | 上海博泰医药科技有限公司 | 一种治疗心脑血管疾病的中药有效部位组合物及其制备方法 |
CN1282654C (zh) * | 2002-12-19 | 2006-11-01 | 上海博泰医药科技有限公司 | 黄芪总皂苷的制备方法 |
CN1201745C (zh) * | 2003-01-10 | 2005-05-18 | 安徽天洋药业有限公司 | 一种含黄芪有效部位的药物组合物 |
-
2003
- 2003-07-29 CN CNB031419275A patent/CN100367969C/zh not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1785202B (zh) * | 2004-12-06 | 2010-12-01 | 天津天士力制药股份有限公司 | 一种治疗心血管疾病的药物组合物及其制备方法 |
CN1314804C (zh) * | 2005-05-20 | 2007-05-09 | 上海中医药大学 | 内源基因超量表达技术提高黄芪甲苷含量 |
CN101507747B (zh) * | 2009-03-21 | 2010-12-01 | 山西振东泰盛制药有限公司 | 黄芪总皂苷氯化钠注射液的制备方法 |
CN101502558B (zh) * | 2009-03-21 | 2011-05-11 | 山西振东泰盛制药有限公司 | 环糊精组合物制备黄芪总皂苷注射液的方法 |
US20120237625A1 (en) * | 2009-11-30 | 2012-09-20 | Amorepacific Corporation | Metabolism accelerating composition comprising astragali radix extract |
US9839660B2 (en) * | 2009-11-30 | 2017-12-12 | Amorepacific Corporation | Metabolism accelerating composition comprising Astragali radix extract |
Also Published As
Publication number | Publication date |
---|---|
CN100367969C (zh) | 2008-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1689575A (zh) | 拟人参皂苷元(Ocotillol)在制备治疗或预防心脑血管疾病的药物中的应用 | |
CN1481806A (zh) | 黄芪总苷注射剂制剂及其制备方法 | |
CN100490843C (zh) | 水红花制剂和制备方法及其应用 | |
CN1415630A (zh) | 银耳多糖,其制备方法和以该化合物为活性成分的药物组合物 | |
CN1297279C (zh) | 一种含丹参素、三七总皂苷和冰片的药物组合物及其制备和应用 | |
CN1686423A (zh) | 一种含有黄芩苷和柴胡的药物组合物及其制备方法 | |
CN1772020A (zh) | 毛冬青冻干粉针剂及其制备方法 | |
CN1823875A (zh) | 一种瓜蒌皮的药物组合物及其制备方法 | |
CN1593489A (zh) | 一种治疗冠心病的中药制剂及其制备方法 | |
CN1096269C (zh) | 一种治心血管病的药物组合物及其制备方法 | |
CN1425379A (zh) | 一种治疗心脑血管疾病的中药有效部位复方制剂及其制备方法 | |
CN1301105C (zh) | 治疗哮喘喷雾剂 | |
CN1919206A (zh) | 牡荆素注射剂及口服制剂 | |
CN1494902A (zh) | 高溶解度小檗碱在制药中的应用 | |
CN1287808C (zh) | 银杏叶提取物组合物 | |
CN1308008C (zh) | 治疗冠心病的药物组合物 | |
CN1281212C (zh) | 西洋参茎叶总皂苷在制备治疗心肌炎的药物中的应用 | |
CN101036714B (zh) | 一种治疗和/或预防糖尿病的药物组合物 | |
CN1634241A (zh) | 治疗心脑血管疾病的复方三七制剂及其制备方法 | |
CN101019878A (zh) | 一种含有丹参丹酚酸a的注射药物组合物及其制备方法 | |
CN1943710A (zh) | 麦冬在心肌炎药物中的应用及其提取物为活性成分的药物 | |
CN1857293A (zh) | 一种含有野黄芩苷和芍药苷的药用组合物 | |
CN1651067A (zh) | 用于治疗和/或预防心脑血管疾病的药物组合物及其制备方法 | |
CN1273107C (zh) | 一种用于预防或治疗冠心病的中药滴丸的制备工艺 | |
CN100444851C (zh) | 菊花总黄酮在制备治疗心律失常药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI JINGFENG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BOTAI MEDICINE SCIENCE AND TECHNOLOGY CO., LTD., SHANGHAI Effective date: 20111101 Owner name: GUIZHOU JINGFENG INJECTION CO.,LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200433 YANGPU, SHANGHAI TO: 201908 BAOSHAN, SHANGHAI |
|
TR01 | Transfer of patent right |
Effective date of registration: 20111101 Address after: Luo Xin Lu Luodian town Baoshan District 201908 Shanghai City No. 50 Co-patentee after: GUIZHOU JINGFENG INJECTION Co.,Ltd. Patentee after: SHANGHAI JINGFENG PHARMACEUTICAL Co.,Ltd. Address before: 3021 room 335, No. 200433, National Road, Shanghai Patentee before: SHANGHAI BOTAI MEDICINE SCIENC |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: Luo Xin Lu Luodian town Baoshan District 201908 Shanghai City No. 50 Patentee after: SHANGHAI JINGFENG PHARMACEUTICAL Co.,Ltd. Patentee after: GUIZHOU JINGFENG INJECTION Co.,Ltd. Address before: Luo Xin Lu Luodian town Baoshan District 201908 Shanghai City No. 50 Patentee before: SHANGHAI JINGFENG PHARMACEUTICAL Co.,Ltd. Patentee before: GUIZHOU JINGFENG INJECTION Co.,Ltd. |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: Luo Xin Lu Luodian town Baoshan District 201908 Shanghai City No. 50 Patentee after: SHANGHAI JINGFENG PHARMACEUTICAL Co.,Ltd. Patentee after: GUIZHOU JINGFENG INJECTION Co.,Ltd. Address before: Luo Xin Lu Luodian town Baoshan District 201908 Shanghai City No. 50 Patentee before: SHANGHAI JINGFENG PHARMACEUTICAL Co.,Ltd. Patentee before: GUIZHOU JINGFENG INJECTION Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080213 Termination date: 20210729 |